Calyxt, Inc. (CLXT)

NASDAQ: CLXT · IEX Real-Time Price · USD
0.160
+0.008 (5.05%)
At close: Dec 1, 2022 4:00 PM
0.189
+0.029 (17.85%)
Pre-market: Dec 2, 2022 4:43 AM EST
5.05%
Market Cap 7.45M
Revenue (ttm) 2.06M
Net Income (ttm) -21.11M
Shares Out 46.78M
EPS (ttm) -0.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 423,656
Open 0.15
Previous Close 0.153
Day's Range 0.15 - 0.172
52-Week Range 0.125 - 2.65
Beta 1.84
Analysts Buy
Price Target 5.61 (+3,401.9%)
Earnings Date Nov 3, 2022

About CLXT

Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. ... [Read more]

Industry Biotechnology
IPO Date Jul 20, 2017
Employees 55
Stock Exchange NASDAQ
Ticker Symbol CLXT
Full Company Profile

Financial Performance

In 2021, Calyxt's revenue was $25.99 million, an increase of 8.96% compared to the previous year's $23.85 million. Losses were -$29.20 million, -34.88% less than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for CLXT stock is "Buy." The 12-month stock price forecast is 5.61, which is an increase of 3,401.87% from the latest price.

Price Target
$5.61
(3,401.87% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Calyxt Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil

ROSEVILLE, Minn. , Nov. 18, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biology company announced today that it has successfully completed the first phase in its research c...

1 week ago - PRNewsWire

Calyxt Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

ROSEVILLE, Minn. , Nov. 17, 2022 /PRNewswire/ -- Calyxt, Inc (Nasdaq: CLXT) a plant-based synthetic biology focused on engineering sustainable ingredients for customers in the cosmeceutical, nutraceutic...

2 weeks ago - PRNewsWire

Calyxt (CLXT) Reports Q3 Loss, Misses Revenue Estimates

Calyxt (CLXT) delivered earnings and revenue surprises of 13.33% and 86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

4 weeks ago - Zacks Investment Research

Calyxt Reports Third Quarter 2022 Financial Results and Provides Corporate Update

— Successfully produced squalene, an important ingredient for personal care products and vaccine adjuvants— — Continued to progress customer acquisition activities, including evaluating an incremental 3...

4 weeks ago - PRNewsWire

Calyxt Joins Bioindustrial Manufacturing and Design Ecosystem (BioMADE), a Department of Defense Initiative, to Advan...

-Calyxt joins a select network of synthetic biology companies, top-tier academic institutions, research-focused not-for-profits, and US government agencies dedicated to innovating and growing the bioeco...

1 month ago - PRNewsWire

Calyxt to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 3, 2022, at 4:3...

ROSEVILLE, Minn. , Oct. 27, 2022 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, November 3, 2022, at 4:30 p.m.

1 month ago - PRNewsWire

Calyxt Successfully Produces Plant-Based Squalene, an Important Ingredient in Personal Care Products and Critical Vac...

ROSEVILLE, Minn. , Oct. 25, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biology company, announced today that using a Calyxt-engineered Plant Cell Matrix™ biomass, it has s...

1 month ago - PRNewsWire

Calyxt Announces Agreement with Evologic Technologies to Scale Production of its Plant-based Ingredients

Agreement will power speed-to-scale strategy to meet the growing interest in high-quality sustainable ingredients across the cosmeceutical, nutraceutical and pharmaceutical markets ROSEVILLE, Minn. , Oc...

1 month ago - PRNewsWire

Calyxt, Inc. Exploring Strategic Alternatives

ROSEVILLE, Minn. , Sept. 22, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT) ("Calyxt"), a plant-based synthetic biology company, today announced that its Board of Directors is evaluating potential str...

2 months ago - PRNewsWire

Calyxt to Present at the H.C. Wainwright 24th Annual Global Investment Conference

ROSEVILLE, Minn. , Sept. 7, 2022 /PRNewswire/ -- Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that Michael A.

2 months ago - PRNewsWire

Bears are Losing Control Over Calyxt (CLXT), Here's Why It's a 'Buy' Now

Calyxt (CLXT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend ...

3 months ago - Zacks Investment Research

Calyxt (CLXT) Reports Q2 Loss, Tops Revenue Estimates

Calyxt (CLXT) delivered earnings and revenue surprises of 6.67% and 36.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Calyxt Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Evaluated nine new customer demand-driven plant-based chemistries in the quarter, bringing cumulative chemistries evaluated for development to 95, of these 31 meet Calyxt's target profile and several ar...

3 months ago - PRNewsWire

Calyxt to Present at the Canaccord Genuity 42nd Annual Growth Conference

ROSEVILLE, Minn. , July 28, 2022 /PRNewswire/ --  Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that Michael A.

4 months ago - PRNewsWire

Calyxt to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 4, 2022, at 4:30...

ROSEVILLE, Minn. , July 21, 2022 /PRNewswire/ --   Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, August 4, 2022, at 4:30 p.m.

4 months ago - PRNewsWire

Calyxt to Present at Upcoming Conferences

ROSEVILLE, Minn. , May 17, 2022 /PRNewswire/ -- Calyxt , Inc.  (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that management will participate in the following upcoming investo...

6 months ago - PRNewsWire

Calyxt (CLXT) Reports Q1 Loss, Misses Revenue Estimates

Calyxt (CLXT) delivered earnings and revenue surprises of 22.22% and 96.24%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Calyxt Reports First Quarter 2022 Financial Results

Achieved technical BioFactory™ and AIML milestones to support customer demand-driven molecule development at scale Progressed relationships with an expanding network of potential new customers across th...

6 months ago - PRNewsWire

Calyxt Announces Strategic Hires in Business Development and Manufacturing

Continued investment in key hires to strategically position Company for future growth and scale ROSEVILLE, Minn. , April 26, 2022 /PRNewswire/ -- Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic bi...

7 months ago - PRNewsWire

Calyxt to Host First Quarter 2022 Financial Results Conference Call and Webcast on Thursday, May 5, 2022, at 4:30 p.m...

ROSEVILLE, Minn. , April 21, 2022 /PRNewswire/ -- Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, May 5, 2022, at 4:30 p.m.

7 months ago - PRNewsWire

Calyxt to Participate in Fireside Chat at the 34th Annual Roth Conference

ROSEVILLE, Minn., March 8, 2022 /PRNewswire/ --  Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that management will participate in a fireside chat at the 34th An...

8 months ago - PRNewsWire

Calyxt (CLXT) Reports Q4 Loss, Misses Revenue Estimates

Calyxt (CLXT) delivered earnings and revenue surprises of 17.39% and 42.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Calyxt Reports Fourth Quarter and Full Year 2021 Financial Results

ROSEVILLE, Minn., March 3, 2022 /PRNewswire/ --  Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic biology company, today announced financial results for its fourth quarter and full year ended Decem...

8 months ago - PRNewsWire

Calyxt to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Thursday, March 3, 2022, at 4:3...

ROSEVILLE, Minn., Feb. 24, 2022 /PRNewswire/ --  Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic biology company, will hold a conference call on Thursday, March 3, 2022, at 4:30 p.m.

9 months ago - PRNewsWire

Calyxt Announces Closing of SEC-Registered Offering of Common Stock, Pre-Funded Warrants to Purchase Common Stock and...

ROSEVILLE, Minn., Feb. 23, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT) ("Calyxt" or the "Company"), a plant-based synthetic biology company, today announced the closing of its previously announced ...

9 months ago - PRNewsWire